Kelly R Pekala1, Jonathan G Yabes2, Jathin Bandari3, Michelle Yu3, Benjamin J Davies3, Lindsay M Sabik4, Jeremy M Kahn5, Bruce L Jacobs6. 1. Department of Urology. Electronic address: pekalak@upmc.edu. 2. Center for Research on Health Care; Division of General Internal Medicine, Department of Medicine. 3. Department of Urology. 4. Center for Research on Health Care; Department of Health Policy and Management, Graduate School of Public Health. 5. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA. 6. Department of Urology; Center for Research on Health Care.
Abstract
OBJECTIVES: To evaluate the impact of centralized surgical and nonsurgical care (i.e., radiation and chemotherapy) on travel distances and survival outcomes for patients with advanced bladder cancer. Bladder cancer is a disease with high mortality for which treatment access is paramount and survival is superior in patients receiving surgery at high-volume centers. METHODS: Using SEER-Medicare, we identified patients 66 years or older diagnosed with bladder cancer between 2004-2013. We categorized patients as treated with either surgical (i.e., radical cystectomy) or nonsurgical (i.e., radiation or chemotherapy) care. We fit a linear probability model to generate the predicted proportion of patients treated at the top quintile of volume over time and assessed travel distance, 1-year all-cause mortality, and 1-year bladder cancer-specific mortality over time. RESULTS: A total of 6,756 and 10,383 patients underwent surgical and nonsurgical care, respectively. The percentage of patients treated at high-volume centers increased over the study period for both surgical care (53% to 62%) and nonsurgical care (47% to 55%), (both P< 0.001). Median travel distance increased (11.8 to 20.3 miles) for surgical care and (6.5 to 8.3 miles) for nonsurgical care, (both P < 0.001). The 1-year adjusted all-cause mortality and 1-year adjusted bladder-cancer specific mortality decreased significantly for both surgical and nonsurgical care (both P < 0.05). CONCLUSIONS: Over time, centralization of surgical and nonsurgical care for bladder cancer patients increased, which was associated with increasing patient travel distance and decreased all-cause and bladder-cancer specific mortality.
OBJECTIVES: To evaluate the impact of centralized surgical and nonsurgical care (i.e., radiation and chemotherapy) on travel distances and survival outcomes for patients with advanced bladder cancer. Bladder cancer is a disease with high mortality for which treatment access is paramount and survival is superior in patients receiving surgery at high-volume centers. METHODS: Using SEER-Medicare, we identified patients 66 years or older diagnosed with bladder cancer between 2004-2013. We categorized patients as treated with either surgical (i.e., radical cystectomy) or nonsurgical (i.e., radiation or chemotherapy) care. We fit a linear probability model to generate the predicted proportion of patients treated at the top quintile of volume over time and assessed travel distance, 1-year all-cause mortality, and 1-year bladder cancer-specific mortality over time. RESULTS: A total of 6,756 and 10,383 patients underwent surgical and nonsurgical care, respectively. The percentage of patients treated at high-volume centers increased over the study period for both surgical care (53% to 62%) and nonsurgical care (47% to 55%), (both P< 0.001). Median travel distance increased (11.8 to 20.3 miles) for surgical care and (6.5 to 8.3 miles) for nonsurgical care, (both P < 0.001). The 1-year adjusted all-cause mortality and 1-year adjusted bladder-cancer specific mortality decreased significantly for both surgical and nonsurgical care (both P < 0.05). CONCLUSIONS: Over time, centralization of surgical and nonsurgical care for bladder cancer patients increased, which was associated with increasing patient travel distance and decreased all-cause and bladder-cancer specific mortality.
Authors: Scott F Huntington; Jessica R Hoag; Weiwei Zhu; Rong Wang; Amer M Zeidan; Smith Giri; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff Journal: Cancer Date: 2018-09-14 Impact factor: 6.860
Authors: Kathryn L Braun; Marjorie Kagawa-Singer; Alan E C Holden; Linda Burhansstipanov; Jacqueline H Tran; Brenda F Seals; Giselle Corbie-Smith; JoAnn U Tsark; Lisa Harjo; Mary Anne Foo; Amelie G Ramirez Journal: J Health Care Poor Underserved Date: 2012-02
Authors: Marc C Smaldone; Jay Simhan; Alexander Kutikov; Daniel J Canter; Russell Starkey; Fang Zhu; Matthew E Nielsen; Karyn B Stitzenberg; Richard E Greenberg; Robert G Uzzo Journal: Urol Oncol Date: 2012-06-09 Impact factor: 3.498
Authors: Jamie S Pak; Danny Lascano; Daniel H Kabat; Julia B Finkelstein; Arindam RoyChoudhury; G Joel DeCastro; William Gold; James M McKiernan Journal: Urol Oncol Date: 2015-07-07 Impact factor: 3.498
Authors: Nathan E Hale; Liam C Macleod; Jonathan G Yabes; Robert M Turner; Mina M Fam; Jeffrey R Gingrich; Ted A Skolarus; Tudor Borza; Lindsay M Sabik; Benjamin J Davies; Bruce L Jacobs Journal: Clin Genitourin Cancer Date: 2019-08-20 Impact factor: 2.872
Authors: Martin F Casey; Juan Wisnivesky; Valerie H Le; Umut Sarpel; Kristian D Stensland; William K Oh; Matthew D Galsky Journal: Bladder Cancer Date: 2016-07-27